Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of
somatotropinomas, thyrotropinomas, and functioning and non-functioning …

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

Hyperprolactinaemia is one of the most common problems in clinical endocrinology. It
relates with various aetiologies (physiological, pharmacological, pathological), the …

Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different
clinical settings and always require an individually tailored approach. This is the reason why …

Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different
clinical settings and always require an individually tailored approach. This is the reason why …

Kisspeptin (KP) and neurokinin B (NKB) are neuropeptides that govern the reproductive
endocrine axis through regulating hypothalamic gonadotropin-releasing hormone (GnRH) …

Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for
prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at …

Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …

Objective A somatic mutational hotspot in the SF3B1 gene was reported in lactotroph
tumours. The aim of our study was to examine the prevalence of driver SF3B1 variants in a …